288 related articles for article (PubMed ID: 31371986)
1. Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer.
Xu ZY; Li JL
Onco Targets Ther; 2019; 12():5467-5484. PubMed ID: 31371986
[TBL] [Abstract][Full Text] [Related]
2. [A review: drug-drug interactions of epithelial growth factor receptor-tyrosine kinase inhibitors].
Zhong J; Wang J
Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):717-724. PubMed ID: 35880337
[TBL] [Abstract][Full Text] [Related]
3. Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
Kucharczuk CR; Ganetsky A; Vozniak JM
J Adv Pract Oncol; 2018 Mar; 9(2):189-200. PubMed ID: 30588353
[TBL] [Abstract][Full Text] [Related]
4. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
Peters S; Zimmermann S; Adjei AA
Cancer Treat Rev; 2014 Sep; 40(8):917-26. PubMed ID: 25027951
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
6. FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced
Solassol I; Pinguet F; Quantin X
Biomolecules; 2019 Oct; 9(11):. PubMed ID: 31671561
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
Zhao Y; Liu J; Cai X; Pan Z; Liu J; Yin W; Chen H; Xie Z; Liang H; Wang W; Guo Z; Zhao S; Liang W; He J
BMJ; 2019 Oct; 367():l5460. PubMed ID: 31591158
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
9. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
Sun JM; Park K
Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
Zhang Y; Zhang Z; Huang X; Kang S; Chen G; Wu M; Miao S; Huang Y; Zhao H; Zhang L
Clin Lung Cancer; 2017 Sep; 18(5):e333-e340. PubMed ID: 28462807
[TBL] [Abstract][Full Text] [Related]
11. A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice.
Slobbe P; Windhorst AD; Stigter-van Walsum M; Smit EF; Niessen HG; Solca F; Stehle G; van Dongen GA; Poot AJ
EJNMMI Res; 2015; 5():14. PubMed ID: 25853020
[TBL] [Abstract][Full Text] [Related]
12. Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients.
Batra U; Lokeshwar N; Gupta S; Shirsath P
Indian J Cancer; 2017 Dec; 54(Supplement):S37-S44. PubMed ID: 29292707
[TBL] [Abstract][Full Text] [Related]
13. Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs).
Mountzios G
Ann Transl Med; 2018 Apr; 6(8):140. PubMed ID: 29862229
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
[TBL] [Abstract][Full Text] [Related]
15. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
16. Turning
Hirsh V
Ther Adv Med Oncol; 2018; 10():1758834017753338. PubMed ID: 29383041
[TBL] [Abstract][Full Text] [Related]
17. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.
Popat S; Mok T; Yang JC; Wu YL; Lungershausen J; Stammberger U; Griebsch I; Fonseca T; Paz-Ares L
Lung Cancer; 2014 Aug; 85(2):230-8. PubMed ID: 24929780
[TBL] [Abstract][Full Text] [Related]
18. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
19. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
20. Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
Zhao J; Guerrero A; Kelnar K; Peltier HJ; Bader AG
Lung Cancer; 2017 Jun; 108():96-102. PubMed ID: 28625657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
